大眾交通(600611.SH):2022年度預虧2.37億至3.41億元
格隆匯1月30日丨大眾交通(600611.SH)公佈,公司預計2022年年度歸屬於上市公司股東的淨利潤與上年同期(法定披露數據)相比,將出現虧損,預計2022年年度實現歸屬於上市公司股東淨利潤-2.37億元到-3.41億元;
預計2022年年度實現歸屬於上市公司股東的扣除非經常性損益的淨利潤-7600萬元到-11000萬元。
主營業務影響:因疫情及其後續連鎖反應,公司下屬交通汽服產業、房產酒店產業均受到了較為明顯的不利影響,導致公司部分日常經營業務收入大幅減少。
非經營性損益的影響:受資本市場波動影響,公司持有的交易性金融資產公允價值下跌導致公允價值變動損失金額較大。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.